Introduction
Medullary thyroid carcinoma (MTC) is a relatively rare type of thyroid cancer, originating from parafollicular cells. It occurs in a sporadic (75%) and in a familial form (25%): multiple endocrine neoplasia (MEN) II syndrome. Distant metastases from MTC usually occur in lungs, bones, liver, and infrequently in brain.
Peritoneal carcinomatosis is defined as an advanced stage of abdominal neoplastic disease (gynecological tumors, gastrointestinal carcinomas, and rarer peritoneal sarcoma or mesothelioma). An extraabdominal primary cancer causing peritoneal carcinomatosis is rare (it has been reported with lung cancer or breast cancer). The prevalence could be underestimated, as suggested by autopsy findings. Besic et al. reported that in 13% of 45 patients with anaplastic thyroid carcinoma, a mesentery or peritoneum site of distant metastasis was detected at autopsy [1] . In our patient, peritoneal carcinomatosis was isolated, which remains uncommon.
To our knowledge, this is the first case of an isolated peritoneal carcinomatosis associated with MTC.
Case Report
A 38-year-old male presenting with voluminous cervical lymph nodes, a thyroid solid tumor on computed tomography (CT) scan, and high calcitonine (8050 ng/L) was diagnosed with MTC. He underwent surgery (total thyroidectomy, central and lateral lymph node dissection). Pathological examination revealed a 9-cm MTC with extrathyroidal extension and 11 positive lymph nodes of the 87 examinated, staged pT4apN1b. Radiotherapy (63 Gy) on cervical site was performed after surgery.
A familial genetic screening revealed the same RET (rearranged during transfection) proto-oncogene mutation (L790F, Leucine790 Phenylalanine) in the patient's blood, in his father considered as index case (72 years old) and in his daughter (10 years old).
Six months after treatment, calcitonine decreased to 48 ng/L. However, an important increase of calcitonine was observed 6 (613 ng/L) and 9 months later (1314 ng/L). Carcino-embryonic antigen (CEA) and urinary catecholamines were both negative. No evidence of pheochromocytoma was found. CT and magnetic (Fig. 1) showed significant uptake in the peritoneal nodes (higher in 18 F-DOPA than in 18 F-FDG), without increased uptake on the head and neck region. MiBg-I123 scintigraphy and Somatostatin Receptor Scintigraphy (SRS) were both negative.
A retroperitoneal node's biopsy was performed and showed a morphological and immunohistochemical profile confirming the medullary carcinoma's origin (tumoral cells with positive calcitonine, synaptophysine, and TTF1 (thyroid transcription factor 1). CEA was negative. RET mutation was positive in the node (with the same mutation as found in blood: L790F, exon 13).
A treatment with tyrosine kinase inhibitors (VANDE-TANIB) was started.
Discussion
We report the case of a patient presenting with a hereditary form of MTC, without pheochromocytoma or hyperparathyroidism and with a L790F mutation in the RET protooncogene, in blood test and in a retroperitoneal node.
Hereditary MTC is caused by autosomal dominant gain-of-function mutations in the RET proto-oncogene. Germ-line mutation in the RET proto-oncogene in exons 10, 11 and less frequently in 13, 14, 15, and 16 are found in most of the familial cases (nearly 95%) [2] . L790F is a point mutation of DNA (deoxyribonucleic acid) change from TTG to TTT, resulted amino acid change from Leucine to Phenylalanine, first reported in 1998 by Berndt et al. [3] . Several studies report an association between the L790F mutation and the development of pheochromocytoma [4] . L790F mutation is usually associated with indolent disease; however, our patient presented bad prognosis criteria such as short CEA doubling time (from 613 to 1314 ng/L in 3 months).
18 F-FDOPA PET/CT showed isolated high uptake in the peritoneal nodes. We know that 18 F F-DOPA PET/CT is a useful supplement to morphological diagnostic imaging [5] . A recent study of Imperiale et al. suggests that 18 F-DOPA is a sensitive functional imaging for the detection of primary neuroendocrine tumors occult on SRS, particularly if the tumor shows a low proliferation index and high level of serotonin or calcitonine [6] . Our case report suggests that 18 F-FDOPA PET/CT could be used with a good accuracy in patients presenting MTC, especially with a L790F-RET mutation, to diagnose metastatic spread (such as peritoneal carcinomatosis); other studies with more patients are necessary to determine the place of 18 F-FDOPA in the diagnosis of peritoneal metastases from MTC. Therapeutic options in metastatic MTC are limited. In 10-20% of cases, a short and moderate response is reported using doxorubicin. Tyrosine kinase inhibitors (TKI) are proposed for the treatment of progressive MTC without possibility of surgical treatment, in locally advanced or metastatic disease [7] .
After discussion in national multidisciplinary meeting, we proposed a treatment by TKI (Vandetanib). After 3 months of treatment, we observed an excellent response with a major decrease of Calcitonine (from 1250 to 33 ng/mL) and significant decrease of the metastatic nodes on MRI. Only minor adverse effects were observed (passing skin rash, minor diarrhea).
A surgical treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermia intraperitoneal chemotherapy (HIPEC) was discussed, as it is classically used in disseminated peritoneal surface malignant disease and offers good results in tumoral control. However, there are currently no reports on literature for this aggressive treatment in this particular context. Other studies are necessary to determine its potential efficiency.
Conclusion
We report the first case of MTC with proved metastatic isolated localization of peritoneal carcinomatosis, confirmed by pathological examination. This case suggests that 18 F-FDOPA may be interesting in the diagnosis of peritoneal nodes of unknown primitive in patients presenting with MTC, especially if bad prognosis criteria are observed. We observed an excellent response at 3 months of treatment by Vandetabib. The place of other specific treatments as HIPEC has to be evaluated in this particular context.
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